BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 34343821)

  • 21. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
    Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
    Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plexin-B2 facilitates glioblastoma infiltration by modulating cell biomechanics.
    Huang Y; Tejero R; Lee VK; Brusco C; Hannah T; Bertucci TB; Junqueira Alves C; Katsyv I; Kluge M; Foty R; Zhang B; Friedel CC; Dai G; Zou H; Friedel RH
    Commun Biol; 2021 Jan; 4(1):145. PubMed ID: 33514835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Upregulation of miR-130b enhances stem cell-like phenotype in glioblastoma by inactivating the Hippo signaling pathway.
    Zhu G; Wang Y; Mijiti M; Wang Z; Wu PF; Jiafu D
    Biochem Biophys Res Commun; 2015 Sep; 465(2):194-9. PubMed ID: 26241672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Downregulation of RND3/RhoE in glioblastoma patients promotes tumorigenesis through augmentation of notch transcriptional complex activity.
    Liu B; Lin X; Yang X; Dong H; Yue X; Andrade KC; Guo Z; Yang J; Wu L; Zhu X; Zhang S; Tian D; Wang J; Cai Q; Chen Q; Mao S; Chen Q; Chang J
    Cancer Med; 2015 Sep; 4(9):1404-16. PubMed ID: 26108681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. mTORC2 regulates hedgehog pathway activity by promoting stability to Gli2 protein and its nuclear translocation.
    Maiti S; Mondal S; Satyavarapu EM; Mandal C
    Cell Death Dis; 2017 Jul; 8(7):e2926. PubMed ID: 28703798
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TNFAIP3 Interacting Protein 3 Is an Activator of Hippo-YAP Signaling Protecting Against Hepatic Ischemia/Reperfusion Injury.
    Zhou J; Hu M; He M; Wang X; Sun D; Huang Y; Cheng X; Fu J; Cai J; Ma T; Tian S; Hu Y; Hu F; Liu D; He Y; Yan L; She ZG; Zhang XJ; Ji YX; Liu H; Li H; Yang H; Zhang P
    Hepatology; 2021 Oct; 74(4):2133-2153. PubMed ID: 34133792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EphB2 receptor controls proliferation/migration dichotomy of glioblastoma by interacting with focal adhesion kinase.
    Wang SD; Rath P; Lal B; Richard JP; Li Y; Goodwin CR; Laterra J; Xia S
    Oncogene; 2012 Dec; 31(50):5132-43. PubMed ID: 22310282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LRIG2 promotes the proliferation and cell cycle progression of glioblastoma cells in vitro and in vivo through enhancing PDGFRβ signaling.
    Xiao Q; Dong M; Cheng F; Mao F; Zong W; Wu K; Wang H; Xie R; Wang B; Lei T; Guo D
    Int J Oncol; 2018 Sep; 53(3):1069-1082. PubMed ID: 30015847
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
    Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma.
    Wu S; Wang S; Zheng S; Verhaak R; Koul D; Yung WK
    Mol Cancer Ther; 2016 Jul; 15(7):1656-68. PubMed ID: 27196759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes.
    Weinberg MA
    Anticancer Drugs; 2016 Jul; 27(6):475-87. PubMed ID: 26918392
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MicroRNA-377 inhibited proliferation and invasion of human glioblastoma cells by directly targeting specificity protein 1.
    Zhang R; Luo H; Wang S; Chen W; Chen Z; Wang HW; Chen Y; Yang J; Zhang X; Wu W; Zhang SY; Shen S; Dong Q; Zhang Y; Jiang T; Lu D; Zhao S; You Y; Liu N; Wang H
    Neuro Oncol; 2014 Nov; 16(11):1510-22. PubMed ID: 24951112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.
    Morrison Joly M; Williams MM; Hicks DJ; Jones B; Sanchez V; Young CD; Sarbassov DD; Muller WJ; Brantley-Sieders D; Cook RS
    Breast Cancer Res; 2017 Jun; 19(1):74. PubMed ID: 28666462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulation of mTORC2 Signaling.
    Fu W; Hall MN
    Genes (Basel); 2020 Sep; 11(9):. PubMed ID: 32899613
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ZWINT: A potential therapeutic biomarker in patients with glioblastoma correlates with cell proliferation and invasion.
    Yang L; Han N; Zhang X; Zhou Y; Chen R; Zhang M
    Oncol Rep; 2020 Jun; 43(6):1831-1844. PubMed ID: 32323832
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas.
    Gini B; Zanca C; Guo D; Matsutani T; Masui K; Ikegami S; Yang H; Nathanson D; Villa GR; Shackelford D; Zhu S; Tanaka K; Babic I; Akhavan D; Lin K; Assuncao A; Gu Y; Bonetti B; Mortensen DS; Xu S; Raymon HK; Cavenee WK; Furnari FB; James CD; Kroemer G; Heath JR; Hege K; Chopra R; Cloughesy TF; Mischel PS
    Clin Cancer Res; 2013 Oct; 19(20):5722-32. PubMed ID: 24030701
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance.
    Masui K; Tanaka K; Ikegami S; Villa GR; Yang H; Yong WH; Cloughesy TF; Yamagata K; Arai N; Cavenee WK; Mischel PS
    Proc Natl Acad Sci U S A; 2015 Jul; 112(30):9406-11. PubMed ID: 26170313
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional Impacts of the BRCA1-mTORC2 Interaction in Breast Cancer.
    Krieger KL; Hu WF; Ripperger T; Woods NT
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma.
    Hou G; Zhao Q; Zhang M; Fan T; Liu M; Shi X; Ren Y; Wang Y; Zhou J; Lu Z
    Biomed Pharmacother; 2018 Oct; 106():1348-1356. PubMed ID: 30119206
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metformin treatment reduces temozolomide resistance of glioblastoma cells.
    Yang SH; Li S; Lu G; Xue H; Kim DH; Zhu JJ; Liu Y
    Oncotarget; 2016 Nov; 7(48):78787-78803. PubMed ID: 27791206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.